Erratum to: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer
Scott LJ, Yang LPH, Lyseng-Williamson KA. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. Drugs Aging 2012; 29 (3): 243–8
“Only second-line therapy available that prolongs overall survival” has now been corrected as follows:
“Only second-line hormonal therapy currently shown to prolong overall survival”
All online versions of this article have been updated to reflect this correction.